Oramed Pharmaceuticals logo
Oramed Pharmaceuticals
ORMP | NASDAQ
Chart Builder DCF Calculator
$3.90
+$0.19 (+5.12%)
At close: Nov 16, 2026, 4:00 PM ET
$3.89
-$0.01 (-0.26%)
After-hours: Nov 16, 2026, 7:01 PM ET

Oramed Pharmaceuticals Company Profile

Company profile explained

Company Profile

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

Key Executives

Name Position
Nadav Kidron President, Chief Executive Officer & Executive Chairman
Avraham Gabay Chief Financial Officer, Treasurer & Secretary
Joshua Hexter Chief Operating & Business Officer
Miriam Kidron Chief Scientific Officer & Director

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 17, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 10, 2026 10-Q Quarterly Report
Aug 03, 2026 ARS Filing
View All SEC Filings ➞
Oramed Pharmaceuticals
Oramed Pharmaceuticals logo
Country United States
IPO Date May 1, 2007
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Nadav Kidron

Contact Details

1185 Avenue of the Americas New York City, New York 10036 United States

Stock Details

Ticker Symbol ORMP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001176309
CUSIP Number 68403P203
ISIN Number US68403P2039
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.